June 14, 2022
On the back of quality and supply issues swirling around the generic industry, authorized generics (AGs) are expanding their market shares, with a huge jump seen with AG penetration for Blopress (candesartan) and Kipres/Singulair (montelukast). When it comes to Talion...read more